Showing 1201-1210 of 1308 results for "".
- Aldeyra Therapeutics Announces Potential of ADX-629 to Treat COVID-19 Patientshttps://modernod.com/news/aldeyra-therapeutics-announces-potential-of-adx-629-to-treat-covid-19-patients/2477578/Aldeyra Therapeutics, which has several drug candidates for the treatment of ocular inflammatory diseases, plans to facilitate the clinical testing of its drug candidate ADX-629 in patients with COVID-19-associated respiratory compromise. The company has requested a pre-investigational new drug m
- Novavax Accelerates Initiation of COVID-19 Vaccine Trial to Mid-Mayhttps://modernod.com/news/novavax-accelerates-initiation-of-covid-19-vaccine-trial-to-mid-may/2477554/Novavax announced it has identified a coronavirus vaccine candidate, NVX-CoV2373, a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology, and will initiate a first-in-human trial in mid-May. Novavax’ proprietary Matrix-M adjuvant will be incorporated w
- Mayo Clinic’s Jonathan Holmes, MD, Appointed UArizona Chair of Ophthalmologyhttps://modernod.com/news/mayo-clinics-jonathan-holmes-md-appointed-uarizona-chair-of-ophthalmology/2477537/Jonathan M. Holmes, MD, has been appointed chair of the University of Arizona College of Medicine – Tucson Department of Ophthalmology, effective Friday, July 31. Dr. Holmes currently serves as the Joseph E. and Rose Marie Green Professor of Visual Sciences and professor of ophthalmology a
- Aldeyra Announces Strategic Prioritization of Late-Stage Clinical Pipeline in Ocular Diseasehttps://modernod.com/news/aldeyra-announces-strategic-prioritization-of-late-stage-clinical-pipeline-in-ocular-disease/2477378/Aldeyra Therapeutics announced strategic prioritization of late-stage ocular disease programs in allergic conjunctivitis, dry eye disease, and proliferative vitreoretinopathy. In conjunction with the strategic prioritization, Aldeyra appointed ophthalmology drug development expert James A. Gow, M
- ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosahttps://modernod.com/news/proqr-receives-orphan-drug-designation-from-fda-for-qr-1123-for-autosomal-dominant-retinitis-pigmentosa/2477112/ProQR Therapeutics announced that it received orphan drug designation (ODD) from the FDA for QR-1123, a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H m
- Iveric bio Appoints Abraham Scaria, PhD, as Chief Scientific Officerhttps://modernod.com/news/iveric-bio-appoints-abraham-scaria-phd-as-chief-scientific-officer/2477050/Iveric bio announced the appointment of Abraham Scaria, PhD, to the position of Chief Scientific Officer, effective October 29, 2019. Dr. Scaria will lead the company’s research and preclinical gene therapy activities. Dr. Scaria’s extensive experience includes positions at Genzyme, Sanofi, and m
- Kodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at The Retina Society Annual Meetinghttps://modernod.com/news/kodiak-sciences-announces-emerging-durability-data-from-ongoing-phase-1b-study-of-ksi-301-in-wet-amd-patients-at-the-retina-society-annual-meeting/2476886/Kodiak Sciences announced emerging durability data in patients with wet age-related macular degeneration (AMD) treated in its phase 1b clinical study of its investigational therapy KSI-301. The results were presented by David M. Brown</
- Alan R. Morse, JD, PhD, Vision and Healthcare Services Innovator, Will Retire As President & CEO of Lighthouse Guildhttps://modernod.com/news/alan-r-morse-jd-phd-vision-and-healthcare-services-innovator-will-retire-as-president-ceo-of-lighthouse-guild/2476695/James M. Dubin, Chairman of the Board of Lighthouse Guild, announced that Alan R. Morse, JD, PhD, will be stepping down later this year as President & CEO of Lighthouse Guild after an extraordinary career of almost 52 years as a leader and innovator in the field
- Innovent Announces First Patient Dosed in a Phase 1 Clinical Trial of IBI302 for the Treatment of Wet AMDhttps://modernod.com/news/innovent-announces-first-patient-dosed-in-a-phase-1-clinical-trial-of-ibi302-for-the-treatment-of-wet-amd/2476478/Innovent Biologics announced that the first patient has been successfully dosed in a phase 1 clinical trial of IBI302, a novel recombinant fully human bispecific fusion protein targeting both vascular endothelium growth factor (VEGF) and complement proteins, for the treatment of wet age-related m
- Raynor Host Surgical Skills Program to Surgical Luminarieshttps://modernod.com/news/raynor-host-surgical-skills-program-to-surgical-luminaries/2476445/Over 50 eye surgeons specializing in cataract and refractive surgery attended a Surgical Skills Program at the Macdonald Hotel, Piccadilly, Manchester. The training session, for surgeons based in Manchester and surrounding areas, was hosted by Rayner. The program was chaired by Professor M